drugset / Trial / NCT00027911
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective in treating soft tissue sarcoma. PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with sargramostim in treating patients who have stage II, stage III, or stage IV soft tissue sarcoma.
Timeline
- Start
- 2001-04
- Primary completion
- 2005-06
- Completion
- 2005-06
Outcome
Outcome not reported
Stopped: “Departure of PI”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NY-ESO-1 peptide vaccine | Vaccine | — | — |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |